Related Party Transactions |
9 Months Ended |
|---|---|
Sep. 30, 2026 | |
| Related Party Transactions [Abstract] | |
| Related Party Transactions | 16. Related Party Transactions
Operating Lease
The Company leases a building for the production of therapeutic radiopharmaceuticals and for research and development from one of the Company’s investors. The terms of the lease were negotiated on an arm’s-length basis. The lease commenced in February 2021 and expires in January 2031. The lease requires monthly base rent of $6 and is accounted for as an operating lease. Operating lease cost related to this lease was $18 for each of the three months ended September 30, 2026 and 2025, and $55 for each of the nine months ended September 30, 2026 and 2025. As of September 30, 2026 and December 31, 2025, the Company’s operating lease right-of-use assets were $286 and $330, respectively, and total operating lease liabilities were $280 and $324, respectively. Of the total lease liabilities, $54 and $56 were classified as current liabilities as of September 30, 2026 and December 31, 2025, respectively, with the remaining $226 and $268 classified as long-term liabilities, respectively.
2023 Term Loan
The Company had an outstanding term loan balance with an existing investor who is a related party. In connection with the Merger, the term loan was repaid in full. See Note 5, Short-Term Debt, for additional information.
Related Party Advances and Promissory Notes
In January 2026, the Company received unsecured, non-interest-bearing advances of $330 from a board member of Legacy Ionetix and $30 from an executive officer. The $30 advance was repaid in February 2026, while the $330 advance was converted into an unsecured promissory note in March 2026. During March 2026, the Company also issued two additional unsecured promissory notes to the same board member with an aggregate principal amount of $575. In April 2026, the Company received an additional non-interest-bearing advance of $350 from the same board member. In connection with the Merger in April 2026, all outstanding promissory notes and advances from the board member were repaid in full, including all outstanding principal and accrued interest. This board member served on the board of directors of Legacy Ionetix at the time of these transactions and did not become a member of the Company’s board of directors upon the closing of the Merger. As of September 30, 2026 and December 31, 2025, no related party advances were outstanding. See Note 5, Short-Term Debt, for additional information. |